{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001569","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.008490+00:00","generated_at":"2026-06-22T01:40:58.175034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum Q3 LIVMARLI sales $18.8M; raises FY2022 guidance to $70M","bullets":["Net product sales LIVMARLI $18.8M in Q3; YTD $47.2M; raised FY2022 guidance to $70M.","Reported Q3 net loss $35.7M ($1.02/share) vs $47.1M loss ($1.55/share) in Q3 2021.","Positive CHMP opinion for LIVMARLI in Alagille syndrome; EU decision expected Q4 2022.","Positive Phase 3 MARCH data in PFIC; completed public offering netting $86.1M.","Cash $285.3M at Sept 30; upcoming data: EMBARK Ph2b H2 2023, OHANA Ph2b H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001569","json":"https://secwatch.observer/filing/0001157523-22-001569.json","markdown":"https://secwatch.observer/filing/0001157523-22-001569.md","text":"https://secwatch.observer/filing/0001157523-22-001569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/0001157523-22-001569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/a52964746.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:40:58.175034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea30a1072c77c20ede1646a7ee46fa34477ce4aa","claim":"Mirum Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: revenue $18.8 million, net income net loss of $35.7 million, EPS $1.02 basic and diluted net loss per share.","evidence_excerpt":"99.1 Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million - Conference call to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/0001157523-22-001569-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$18.8 million"},{"label":"Net income","value":"net loss of $35.7 million"},{"label":"EPS","value":"$1.02 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}